Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Future of anti-BCMA CAR T-cell therapy in myeloma

Noopur Raje • 1 Sep 2020
EBMT 2020
Multiple Myeloma
KarMMa

Noopur Raje, MD, Massachussetts General Hospital, Boston, MA, discusses areas of improvement in anti-BCMA CAR T-cell therapy in multiple myeloma, including evaluating the durability of response to CAR T-cell therapy, as well as the use of off-the-shelf allogeneic CAR-T. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Noopur Raje

8:14
Current CAR-T climate in multiple myeloma
Noopur Raje • 1 Sep 2020

Related Videos

2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
The content of VJRegenMed is intended for healthcare professionals